Rinvoq Dosage/Direction for Use

Treatment with upadacitinib should be initiated and supervised by physicians experienced in the diagnosis and treatment of conditions for which upadacitinib is indicated.
Posology: Rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis: The recommended dose of upadacitinib is 15 mg once daily.
Consideration should be given to discontinuing treatment in patients with ankylosing spondylitis who have shown no clinical response after 16 weeks of treatment. Some patients with initial partial response may subsequently improve with continued treatment beyond 16 weeks.
Atopic dermatitis: Adults: The recommended dose of upadacitinib is 15 mg or 30 mg once daily based on individual patient presentation.
A dose of 30 mg once daily may be appropriate for patients with high disease burden.
A dose of 30 mg once daily may be appropriate for patients with an inadequate response to 15 mg once daily.
The lowest effective dose for maintenance should be considered.
For patients ≥65 years of age, the recommended dose is 15 mg once daily.
Adolescents (from 12 to 17 years of age): The recommended dose of upadacitinib is 15 mg once daily for adolescents weighing at least 40 kg.
RINVOQ has not been studied in adolescents weighing less than 40 kg.
Concomitant topical therapies: Upadacitinib can be used with or without topical corticosteroids. Topical calcineurin inhibitors may be used for sensitive areas such as the face, neck, and intertriginous and genital areas.
Dose initiation: Treatment should not be initiated in patients with an absolute lymphocyte count (ALC) that is <0.5 x 10⁹ cells/L, an absolute neutrophil count (ANC) that is <1 x 10⁹ cells/L or who have haemoglobin (Hb) levels that are <8 g/dL (see Precautions and Adverse Reactions).
Dose Interruption: Treatment should be interrupted if a patient develops a serious infection until the infection is controlled.
Interruption of dosing may be needed for management of laboratory abnormalities as described in Table 13. (See Table 13.)

Click on icon to see table/diagram/image

Special populations: Elderly: For atopic dermatitis, doses higher than 15 mg once daily are not recommended in patients aged 65 years and older (see Adverse Reactions).
There are limited data in patients aged 75 years and older.
Renal Impairment: No dose adjustment is required in patients with mild or moderate renal impairment. There are limited data on the use of upadacitinib in subjects with severe renal impairment (see Pharmacology: Pharmacokinetics under Actions). Upadacitinib 15 mg once daily should be used with caution in patients with severe renal impairment. Upadacitinib 30 mg once daily is not recommended for patients with severe renal impairment. The use of upadacitinib has not been studied in subjects with end stage renal disease.
Hepatic Impairment: No dose adjustment is required in patients with mild (Child Pugh A) or moderate (Child Pugh B) hepatic impairment (see Pharmacology: Pharmacokinetics under Actions). Upadacitinib should not be used in patients with severe (Child Pugh C) hepatic impairment (see Contraindications).
Paediatric population: The safety and efficacy of RINVOQ in adolescents weighing < 40 kg and in children aged 0 to less than 12 years have not yet been established. No data are available.
The safety and efficacy of RINVOQ in children and adolescents with rheumatoid arthritis and psoriatic arthritis aged 0 to less than 18 years have not yet been established. No data are available.
Method of administration: RINVOQ is to be taken orally once daily with or without food and may be taken at any time of the day. Tablets should be swallowed whole and should not be split, crushed, or chewed in order to ensure the entire dose is delivered correctly.
Missed Dose: If a dose of RINVOQ is missed and it is more than 10 hours from the next scheduled dose, advise the patient to take a dose as soon as possible and then to take the next dose at the usual time. If a dose is missed and it is less than 10 hours from the next scheduled dose, advise the patient to skip the missed dose and take only a single dose as usual the following day. Advise the patient not to double a dose to make up for a missed dose.